Biogen Inc. (BIIB)

226.39
NASDAQ
Prev Close 227.18
Day Low/High 221.53 / 227.88
52 Wk Low/High 216.12 / 388.67
Exchange NASDAQ
Shares Outstanding 196.71B
Market Cap 44.69B
Div & Yield N.A. (N.A)

Latest News

Stepping Carefully Into the Second Quarter

Stepping Carefully Into the Second Quarter

The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.

How I Use Options to Mitigate Risk and Create Income

How I Use Options to Mitigate Risk and Create Income

Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Powell and Company Can Influence the Macro, but Not the Micro

Powell and Company Can Influence the Macro, but Not the Micro

All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.

Volatile Biogen Stock Plunges $90: Here's the Trade I'm Considering

Volatile Biogen Stock Plunges $90: Here's the Trade I'm Considering

Biogen shareholders are taking a beating on cancellation of trials for its Alzheimer's drug candidate.

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.

Biogen Could Go Either Way - Mixed Indicators and Charts

Biogen Could Go Either Way - Mixed Indicators and Charts

Let's check to see what can be gleaned.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Biogen Rated at BTIG

Biogen's Slump Is Likely to Continue

Biogen's Slump Is Likely to Continue

Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.

The Real Money Post-Industrial Average Has Jumped 11% So Far This Year

The Real Money Post-Industrial Average Has Jumped 11% So Far This Year

For the month of November RMPIA climbed 1.2% month over month.

Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half

Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half

Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Big Swings in Biogen Make It Hard to Take New Positions

Big Swings in Biogen Make It Hard to Take New Positions

Short-term price action may be volatile, but this name is still bullish long term.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

Jim Cramer: We've Got an Extremist Market

Jim Cramer: We've Got an Extremist Market

Don't buy up when there's nothing but rampant pin action.

Biogen Downgraded to Neutral at Baird

2 Small Biotechs I Like in the Second Half

2 Small Biotechs I Like in the Second Half

Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.

Biogen Stock: A Long-Term Bullish Perspective

Biogen Stock: A Long-Term Bullish Perspective

After Friday's surge another look at BIIB is warranted.

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.

Video: Jim Cramer on the Jobs Report, Tariffs and Biogen

Video: Jim Cramer on the Jobs Report, Tariffs and Biogen

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Midday Musings

At midday tech, biotech ( dragging the group higher), homebuilders and energy are leading to the upside. There are really no large underperformers - though on a relative sense, autos, cap goods and semis are trailing. Banks fell initially, on the "d...

Biogen: Let the Situation Cool Off a Bit Before Buying

Biogen: Let the Situation Cool Off a Bit Before Buying

There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

This biotech's weekly chart is very encouraging.

Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.